First in Human Study of M6223 in Participants With Metastatic or Locally Advanced Solid Unresectable Tumours

Official Title

Phase I, First-in-Human, Open-Label, Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of M6223, an Inhibitor of TIGIT, as Single Agent and in Combination With Bintrafusp Alfa, Anti-PDL1/ TGFß Trap in, Participants With Metastatic or Locally Advanced Solid Unresectable Tumours

Summary:

The main purpose of this study is to determine the safety, tolerability, pharmacokinetics (PK), immunogenicity and (if observed) the maximum tolerated dose (MTD) of M6223 as a single agent (Part 1A) and of M6223 combined with bintrafusp alfa (Part 1B) in participants with metastatic or locally advanced solid unresectable tumours.

Trial Description

Primary Outcome:

  • Part 1A and 1B: Occurrence of Dose Limiting Toxicities (DLTs) During the DLT Observation Period (28 Days)
  • Part IA and IB: Occurrence of Treatment-Emergent Adverse Events (TEAEs) and Treatment Related Adverse Events (TRAEs) According to the National Cancer Institute Common Terminology Criteria of Adverse Events (NCI-CTCAE) version 5
  • Part IA and IB: Occurrence of Treatment-Emergent Adverse Events (TEAEs) as per Severity and Deaths
  • Part IA and IB: Occurrence of Clinically Significant Change From Baseline in Clinical Laboratory Measures
  • Part IA and IB: Occurrence of Clinically Significant Change From Baseline in Electrocardiogram Findings
  • Part IA and IB: Occurrence of Clinically Significant Change From Baseline in Vital Signs
  • Part IA and IB: Occurrence of Change From Baseline in Eastern Cooperative Oncology Group Performance Status
Secondary Outcome:
  • Part 1A and Part 1B: Area Under the Serum Concentration-Time Curve From Time Zero to the Last Sampling Time (AUC 0-t) of M6223
  • Part 1A and Part 1B: Area Under the Serum Concentration-Time Curve From Time Zero to Infinity (AUC 0-inf) of M6223
  • Part 1A and Part 1B: Area Under Serum Concentration-Time Curve Over a Dosing Interval From Time Zero to Tau (τ) (AUCτ) of M6223
  • Part 1A and Part 1B: Maximum Observed Serum Concentration (Cmax) of M6223
  • Part 1A and Part 1B: Serum Concentration Observed Immediately Before Next Dosing (Ctrough) of M6223
  • Part 1A and Part 1B: Time to Reach Maximum Serum Concentration (Tmax) of M6223
  • Part 1A and Part 1B: Apparent Terminal Half-Life (t1/2) of M6223
  • Part 1A and Part 1B: Elimination Rate Constant (Lambda z) of M6223
  • Part 1B: Maximum Observed Serum Concentration (Cmax) of Bintrafusp alfa
  • Part 1B: Serum Concentration Observed Immediately Before Next Dosing (Ctrough) of Bintrafusp alfa
  • Part IA and 1B: Immunogenicity of M6223 Measured by Antidrug Antibody (ADA) Assays
  • Part 1B: Immunogenicity of Bintrafusp alfa Measured by Antidrug Antibody (ADA) Assays
  • Part 1A and 1B: Change from Baseline in QT Interval
  • Part 1A and IB: Best Overall Response According to Response Criteria in Solid Tumours Version 1.1 (RECIST 1.1) Assessed as per Investigator
  • Part 1A and 1B: Duration of Response According to Response Criteria in Solid Tumours Version 1.1 (RECIST 1.1) Assessed as per Investigator
  • Part 1A and 1B: Time to Tumour Response According to Response Criteria in Solid Tumours Version 1.1 (RECIST 1.1) Assessed as per Investigator
  • Part 1A and 1B: Disease Control According to Response Criteria in Solid Tumours Version 1.1 (RECIST 1.1) Assessed as per Investigator
  • Part 1A and 1B: Progression-free Survival Time According to Response Criteria in Solid Tumours Version 1.1 (RECIST 1.1) Assessed as per Investigator
  • Part 1A and 1B: Overall Survival

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society